Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 15 to 23 amino acid residues in defined sequence
Reexamination Certificate
2007-11-27
2007-11-27
Ewoldt, G. R. (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
15 to 23 amino acid residues in defined sequence
C514S002600, C424S185100
Reexamination Certificate
active
10001938
ABSTRACT:
A method of modulating an immune response in a subject is disclosed. The invention is based on the discovery that an effective therapeutic strategy for ameliorating the inflammation-related symptoms of an immune-mediated disease, such as arthritis, can be achieved by modulation of the underlying immune response itself, rather than by merely addressing the resulting inflammation. This strategy can be used to regulate the inflammatory response and is applicable to a variety of contexts in which immune modulation is desired, such as mucosal tolerization, DNA vaccination, anergy induction, active immunization, and ex vivo modulation of antigen-specific T cells. In one embodiment, the method comprises administering to the subject a bacterial dnaJ peptide or a human homolog or a non-homologous human isoform thereof.
REFERENCES:
patent: 4654419 (1987-03-01), Vaughan et al.
patent: 4683295 (1987-07-01), Carson
patent: 4732757 (1988-03-01), Stolle et al.
patent: 5116725 (1992-05-01), Vaughan et al.
patent: 5310732 (1994-05-01), Carson et al.
patent: 5334379 (1994-08-01), Pillai et al.
patent: 5541164 (1996-07-01), Carson et al.
patent: 5728385 (1998-03-01), Classen
patent: 5773570 (1998-06-01), Carson et al.
patent: 5891435 (1999-04-01), Muir et al.
patent: 5992567 (1999-07-01), Au-Young et al.
patent: 5993803 (1999-11-01), Cohen et al.
patent: 6007821 (1999-12-01), Srivastava et al.
patent: WO90/14835 (1990-12-01), None
patent: WO95/31984 (1995-11-01), None
patent: WO 9832772 (1998-07-01), None
Immunology. Kuby, 1992 W. H. Freeman and Company, p. 74.
Fernandes et al. Characterization of MHC class II-presented peptides generated from an antigen targeted to different endocytic compartments, Eur. J. Immunol. 2000, 30:2333-2343.
Link et al., J. Biol. Chem., 2006, 281:1808-1816.
Albani et al., “Positive selection in autoimmunity: Abnormal immune response to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis,” Nature Medicine, 1 (5):448-452, 1995.
McColl et al., “Absence of peripheral blood T cell responses to ‘shared epitope’ containing peptides in recent onset rheumatoid arthritis,”Anals Rheum Dis, 56:240-246 (1997).
McSorely et al., “Selective tolerization of Th1-like cells after nasal administration of a cholers toxoid-LACK conjugate,” Eur. J. Immunol., 28:424-432 (1998).
Vandenbark et al., “Differential susceptibility of human Th1 versus Th2 cells to induction of anergy and apoptosis by EDCI/antigen-coupled antigen-presenting cells,”International Immunology, 12 (1):57-66 (1999).
Bonnin, D., et al., “MHC-Derived Peptides Drive Positive T Cell Selection in the Thymus: from a Physiological System to an HLA DRB1*0401 Transgenic Mouse Model for Rheumatoid Arthritis?”,Arthritis and Rheumatism, vol. 39, No. 9 Suppl., p. S160, Oct. 1996.
Auger, I., et al., “HLA-DR4 and HLA-DR10 Motifs that Carry Susceptibility to Rheumatoid Arthritis Bind 70-kD Heat Shock Proteins,”Nature Medicine, vol. 2, No. 3, pp. 306-310, Mar. 1996.
Albani, et al., “Genetics and Environmental Factors in the Immune Pathogenesis of Rheumatoid Arthritis,”Rheumatic Disease Clinics of North America, 18/4:729-740, 1992.
Stastney, P., et al., “Immunogenetics of Rheumatoid Arthritis and Juvenile Arthritis”,Recenti Progressi in Medicina, vol. 82, No. 7-8, pp. 409-416, 1991.
Nepom, G., “Prediction of Susceptibility to Rheumatoid Arthritis by Human Leukocyte Antigen Genotying”Rheumatic Disease Clinics of North America, vol. 18, No. 4, pp. 785-792, Nov. 1992.
Weyand, C., et al., “The Influence of HLA-DRB1 Genes on Disease Severity in Rheumatoid Arthritis,” Annals of Internal Medicine, vol. 117, No. 10, pp. 801-806, Nov. 15, 1992.
Fairchild, P., et al., “Peptide-MHC Interaction in Autoimmunity,”Current Opinion in Immunology, vol. 4, pp. 748-753, 1992.
Life, P.F., et al., “Synovial Fluid Antigen-Presenting Cells Unmask Peripheral Blood T Cell Responses to Bacterial Antigens in Inflammatory Arthritis,”Clin. Exp. Immunol. vol. 79, pp. 189-194, 1990.
Van Den Broek, M.F., et al., “Protection Against Streptococcal Cell Wall-Induced Arthritis by Pretreatment with the 65-kD Mycobacterial Heat Shock Protein,”J. Exp. Med., vol. 170, pp. 449-466, Aug. 1989.
Anderton, S.M., et al. “Activation of T Cells Recognizing Self 60-kD Heat Shock Protein Can Protect Against Experimental Arthritis,”J. Exp. Med., vol. 181, pp. 943-952, Mar. 1995.
Albani, S., et al., “A Multistep Molecular Mimicry Hypothesis for the Pathogenesis of Rheumatoid Arthritis,”Immunology Today, vol. 17, No. 10, pp. 466-470, Oct. 1996.
Anderton et al, “Differential Mycobacterial 65-kDa Heat Shock Protein T Cell Epitope Recognition after Adjuvant Arthritis-Inducing or Protective Immunization Protocols1,”J. Immunology152:3656-64, 1994.
Albani et al, “HLA Binding Studies Support a Role for the QKRAA Susceptibility Sequence to Rheumatoid Arthritis (RA) in Positive Selection and Activation of Pathogenic T Lymphocytes,”Arthritis and Rheumatism, 38/9 Suppl., p. S181, Abstract#173, 1995.
Plotkin, S.A., et al., “New Technologies for Making Vaccines,”Vaccines, pp. 568-575, 1988.
Albani, S., et al., “Molecular Basis for the Association Between HLA DR4 and Rheumatoid Arthritis. From the Shared Epitope Hypothesis to a Peptidic Model of Rheumatoid Arthritis,”Clin. Biochem. vol. 25, pp. 209-212, 1992.
La Cava, A., et al., “The QKRAA Disease Susceptibility Sequence for Rheumatoid Arthritis (RA) is a B Cell Epitope Shared by the Epstein-Barr Virus (EBV) Protein gp110 and theE. coliHeat Shock Protein dnaJ Possible Implications for Disease Pathogenesis,”Arthritis&Rheum. 36(9) Suppl. pp. S127 Abstract 1993.
Asseldonk, M., et al., “Cloning, Nucleotide Sequence, and Regulatory Analysis of theLactococcus lactic dnaJGene,”,Journal of Bacteriology, 175(6), pp. 1637-1644, Mar. 1993.
Bardwell, J.C.A., et al., “The Nucleotide Sequence of theEscherichia coli K12 dnaJ+ Gene,”The Journal of Biological Chemistry, vol. 261, No. 4, pp. 1782-1785, Feb. 5, 1986.
Ohki, M., et al., “Nucleotide Sequence of theEscherichia coli dnaJGene and Purification of the Gene Product*”, The Journal of Biological Chemistry, vol. 261, No. 4, pp. 1778-1781, 1986.
Albani, S., et al., “The Susceptibility Sequence to Rheumatoid Arthritis is a Cross-Reactive B Cell Epitope Shared by theEscherichia coliHeat Shock Protein dnaJ and the Histocompatibility Leukocyte Antigen DRB10401 Molecule,”J. Clin. Invest., vol. 89, pp. 327-331, 1992.
van Eden, W., et al., “Cloning of the Mycobacterial Epitope Recognized by T Lymphocytes in Adjuvant Arthritis,”Nature, vol. 331, pp. 171-173, Jan. 14, 1988.
Silver, P.A., et al. “Eukaryotic DnaJ Homologs and the Specificity of Hsp70 Activity,”Cell, vol. 74, pp. 5-6, Jul. 16, 1993.
Zuber et al., “Cloning, Sequencing and Expression of thednaJgene ofCoxiella burnetii,” Gene, vol. 152 pp. 99-102, 1995.
DeGraeff-Meeder, E.R., et al., “Recognition of Human 60kD Heat Shock Protein by Mononuclear Cells from Patients with Juvenile Chronic Arthritis,”The Lancet, vol. 337, pp. 1368-1372, Jun. 8, 1991.
Brackertz et al, “OM-8980 in Rheumatoid Arthritis: A 6-Month Double Blind Placebo Controlled Multicenter Study,”Journal of Rheumatology, vol. 16, pp. 19-23, 1989.
Marsh, S.G.E., et al, “HLA Class II Nucleotide Sequences, 1991,”Tissue Antigens, vol. 37, pp. 181-189, 1991.
Albani, S., et al., “Immune Responses to theEscherichia colidnaJ Heat Shock Protein in Juvenile Rheumatoid Arthritis and their Correlation with Disease Activity,”The Journal of Pediatrics, vol. 124, No. 4, pp. 561-565, Apr. 1994.
Gencore Accession #HHECDJ; Date: Jan. 30, 1988; revised Mar. 1, 2002.
Albani Salvatore
Carson Dennis A.
Martini Alberto
Prakken Berent J
DLA Piper (US) LLP
Ewoldt G. R.
Szperka Michael
LandOfFree
Immunomodulatory peptides derived from heat shock proteins... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunomodulatory peptides derived from heat shock proteins..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulatory peptides derived from heat shock proteins... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3817155